University of Lausanne

Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate

Retrieved on: 
måndag, november 15, 2021
Mortality, Safety, Volunteering, University, Immunity, University of Lausanne, Center, Antigen, Dengue fever, Disease, CTLS, Lymphocyte, Severe acute respiratory syndrome coronavirus 2, COVID-19, COVID-19 vaccine, Vaccine, T cell, Virus, Temperature, Public health, Skin, Patient, Pharmaceutical industry

The Phase I trial is a double-blind, randomised and comparator-controlled study of two groups of 13 volunteers at high and low doses.

Key Points: 
  • The Phase I trial is a double-blind, randomised and comparator-controlled study of two groups of 13 volunteers at high and low doses.
  • The first patient is anticipated to receive their first dose of Emergex vaccine candidate at the start of January 2022.
  • A Phase I clinical trial ( NCT04935801 ), named naNO-DENGUE, testing Emergexs Dengue vaccine candidate is currently underway in Switzerland with all patients having received two vaccine doses.
  • We are proud to announce the initiation of this trial and look forward to gathering data to support the development of this important next generation vaccine.

AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors

Retrieved on: 
fredag, oktober 29, 2021
Dermatology, Merck, CH, University of Lausanne, Public policy, GB, Gebert, COVID-19, University of St. Gallen, Acquisition, GLOBE, Neurodegeneration, HIV, Diagnosis, Physician, Swiss National Bank, Honorary degree, RU, Company, World Bank, JP, Leo Pharma, Science, Neurology, AU, Industry, Royal college, University of Zurich, Medical director, NO, Drug development, AC, 2007 Swiss Federal Council election, Genentech, Eli Lilly and Company, Precision medicine, World, Royal College of Physicians, Janssen Pharmaceuticals, EGM, Board of directors, Federal Council, University, Hoffmann-La Roche, NASDAQ, Â, Novartis, Board, Schindler Elevator Corporation, Medical device, Management, Pharmaceutical industry, Medicine

LAUSANNE, Switzerland, Oct. 29, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors. Dr. Shaw and Prof. Bütler replace Mr. Martin Velasco and Peter Bollmann, Ph.D., who stepped down from the Board following the EGM.

Key Points: 
  • Dr. Shaw and Prof. Btler replace Mr. Martin Velasco and Peter Bollmann, Ph.D., who stepped down from the Board following the EGM.
  • We also extend our sincere thanks to Mr. Velasco and Dr. Bollmann, as their contributions as Directors helped to establish AC Immunes position as an industry leader.
  • I look forward to working with my fellow Directors to provide valuable insights and guidance as the Company advances its industry-leading strategy.
  • SupraAntigen is a registered trademark ofAC Immune SAin the following territories: AU, EU, CH, GB, JP and RU.

Global Leaders Gather at International Leadership Association Conference in Geneva, Switzerland and Online

Retrieved on: 
torsdag, oktober 21, 2021
Thunderbird, Inter-Parliamentary Union, Geneva Centre for Security Policy, University of Amsterdam, Multimedia, Policy, Parliament, Research, Travel, Physician, International Red Cross and Red Crescent Movement, Face, Senior, University of Lausanne, Gavi, Association, Chairperson, Harvard University, Industry, Founder, Surgeon, The Right Honourable, Leadership, HYFLEX, Founder CEO, Thunderbird School of Global Management, UN, CEO, Royal College of Physicians and Surgeons of Canada, Security policy, Heart, GCSP, List of international sports federations, House, University, Entrepreneurship, Islamic republic, ILA, Global Governance, GIST, Video game, Management

The UN Secretary General has declared code red for humanity in the wake of the latest IPCC Climate report.

Key Points: 
  • The UN Secretary General has declared code red for humanity in the wake of the latest IPCC Climate report.
  • The ILA's mission of "Advancing leadership knowledge and practice for a better world" and this year's conference theme - Reimagining Leadership Together - could not be more relevant.
  • There's no better city to be having these conversations than Geneva, the heart and soul of global, multilateral organizations and a hub for international leadership.
  • The International Leadership Association is a worldwide professional association committed to advancing leadership knowledge and practice for a better world.

Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO Conference

Retrieved on: 
onsdag, oktober 20, 2021
Spiez Laboratory, Clinical trial, World, DARPin, NASDAQ, Molecular Partners, Death, Risk, WHO, Form, RSV, Twitter, Private Securities Litigation Reform Act, COVID-19, Ophthalmology, Humanitarian use licenses, Part, Incidence, Treatment, Molecule, Security (finance), SPR, University Hospital Center Dr Dragiša Mišović, ACTIV, Surface plasmon resonance, Severe acute respiratory syndrome coronavirus 2, Infection, Complementarity, World Health Organization, International Society, U.S. Securities and Exchange Commission, Investor, NIH, Vaccination, Viral load, Company, GLOBE, Patient, University, RBD, Population, SEC, Novartis, Marketing, Therapy, ACE2, University of Lausanne, Pharmaceutical industry, Vaccine

In addition, the Company will present a Trial in Progress poster on the EMPATHY clinical trial, conducted in collaboration with Novartis.

Key Points: 
  • In addition, the Company will present a Trial in Progress poster on the EMPATHY clinical trial, conducted in collaboration with Novartis.
  • As such, we must continually test ensovibep against new variants to ensure it has the potential to still be relevant for current and future patients.
  • Finally, viral passaging experiments show ensovibep as comparable to monoclonal antibody cocktails with respect to minimizing the development of escape mutants.
  • Molecular Partners and Novartis are collaborating on the development of ensovibep and are evaluating it in global late-stage study.

Accomplished Industry Executive Alan L. Rubino Named Chairman of AMO Pharma Board of Directors

Retrieved on: 
torsdag, augusti 19, 2021
Industry, LLC, Tic disorder, University, Harvard Business School, Acquisition, Science, Economics, Rutgers University, AMO, Therapy, Marketing, Rett syndrome, Genentech, Health, Safety, Patient, CEO, University of Lausanne, Novo Nordisk, Drug development, Pharmaceutical industry

LONDON, Aug. 19, 2021 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no treatment options, today announcedthatAlanL.Rubinohas joined the AMO Pharma board of directors as chairman as of August 16, 2021.

Key Points: 
  • LONDON, Aug. 19, 2021 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no treatment options, today announcedthatAlanL.Rubinohas joined the AMO Pharma board of directors as chairman as of August 16, 2021.
  • "AlanRubinohas extensive experience in all areas of drug development and commercialization and in the planning and execution of many global licensing and acquisition deals in the pharma and life sciences sectors," saidIbraheemMahmood, AMO Pharma chief executive officer.
  • "I am very pleased to be joining the AMO Pharma board of directors as the company continues to build new levels of momentum in its development programs and plans for several major clinical milestones," said Mr.Rubino.
  • For more information, please visit the AMO Pharma website at http://www.amo-pharma.com/ .

Accomplished Industry Executive Alan L. Rubino Named Chairman of AMO Pharma Board of Directors

Retrieved on: 
torsdag, augusti 19, 2021
Industry, LLC, Tic disorder, University, Harvard Business School, Acquisition, Science, Economics, Rutgers University, AMO, Therapy, Marketing, Rett syndrome, Genentech, Health, Safety, Patient, CEO, University of Lausanne, Novo Nordisk, Drug development, Pharmaceutical industry

LONDON, Aug. 19, 2021 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no treatment options, today announcedthatAlanL.Rubinohas joined the AMO Pharma board of directors as chairman as of August 16, 2021.

Key Points: 
  • LONDON, Aug. 19, 2021 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no treatment options, today announcedthatAlanL.Rubinohas joined the AMO Pharma board of directors as chairman as of August 16, 2021.
  • "AlanRubinohas extensive experience in all areas of drug development and commercialization and in the planning and execution of many global licensing and acquisition deals in the pharma and life sciences sectors," saidIbraheemMahmood, AMO Pharma chief executive officer.
  • "I am very pleased to be joining the AMO Pharma board of directors as the company continues to build new levels of momentum in its development programs and plans for several major clinical milestones," said Mr.Rubino.
  • For more information, please visit the AMO Pharma website at http://www.amo-pharma.com/ .